Don Hardison
Biotheranostics has appointed Don Hardison as CEO, succeeding Nicolas Barthelemy. Hardison originally joined Biotheranostics in July 2016 as part of its board of directors. Most recently, he served as president, CEO, and director of Good Start Genetics. He has also served as CEO of Exact Sciences and held senior leadership roles at Laboratory Corporation of America, Quest Diagnostics, and SmithKline Beecham.
John Marshall
Caris Life Sciences has appointed John Marshall as its chief medical officer. In this role, Marshall will direct the company's oncology research efforts, guide clinical strategies for innovative precision medicine and tumor profiling services, and continue to serve as chairman of the Caris Centers of Excellence for Precision Medicine Network. He currently serves as associate director for clinical care at the Georgetown Lombardi and chief of the division of hematology-oncology at MedStar Georgetown University Hospital. Marshall is also the founding director of Georgetown Lombardi's Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer.
Wendy Rubinstein
Wendy Rubinstein has been named the first division director for clinical data management and curation of CancerLinQ, a nonprofit subsidiary of the American College of Clinical Oncology. In this newly created role, Rubinstein will lead all clinical data quality and data curation at CancerLinQ. Rubinstein previously served as chief of medical genetics and human variation at the NIH National Center for Biotechnology Information, director of the NIH Genetic Testing Registry, and in various leadership positions at NorthShore University HealthSystem in Evanston, Illinois.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.